Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
KDNY similar filings
- 20 Nov 20 Other Events
- 10 Nov 20 Departure of Directors or Certain Officers
- 5 Nov 20 Index to Chinook Consolidated Financial Statements
- 7 Oct 20 Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
- 1 Oct 20 Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics
- 24 Sep 20 Regulation FD Disclosure
- 21 Sep 20 Other Events
Filing view
External links
Exhibit 16.1
October 7, 2020
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Chinook Therapeutics, Inc.’s Form 8-K dated October 7, 2020, and have the following comments:
1. | We are in agreement with the statements made in part (a) Dismissal of Independent Registered Public Accounting Firm. |
2. | We have no basis on which to agree or disagree with the statements made in part (b) Engagement of New Independent Registered Public Accounting Firm. |
Yours truly,
/s/ Deloitte & Touche LLP
San Francisco, California